KMPH KemPharm, Inc.

3.40
+0.05  (1%)
Previous Close 3.35
Open 3.40
Price To book 0.00
Market Cap 49.80M
Shares 14,647,000
Volume 7,293
Short Ratio 30.25
Av. Daily Volume 29,378

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 complete. NDA filing due 2019.
KP511/IR 511/ER
Severe pain
Phase 1 trial completed. Further trials to commence 1H 2017, with data end of 2017. NDA filing 2018.
KP201/IR
Acute pain
Phase 1 trial completed December 2016. Efficacy trials to commence 2H 2017, with data 1H 2018.
KP415
ADHD
CRL issued November 2015. Appeal against FDA launched November 2016.
KP201/APAP
Acute pain.